{
  "docId": "019de070-c935-736b-bfac-0e59550f8f0f",
  "docSlug": "bbdd6d1004c11d68b286eff6aee60dc0",
  "documentTitle": "argenx SE | Results Presentation Deck | 20 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 20,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a process flow diagram to illustrate the clinical trial protocol.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-c935-736b-bfac-0e59550f8f0f/10",
  "deckHref": "/decks/019de070-c935-736b-bfac-0e59550f8f0f",
  "deckJsonHref": "/decks/019de070-c935-736b-bfac-0e59550f8f0f.json",
  "deckAnchorHref": "/decks/019de070-c935-736b-bfac-0e59550f8f0f#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.78,
        "y": 0.28
      },
      "kind": "callout",
      "text": "Primary endpoint is proportion of PV patients achieving CRmin* within 30 weeks. N=sample size estimation ≤150 patients (PV and PF) with PF patients capped. Followed by Open Label Extension study",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e15b014-7ba8-4f4c-beef-ac048535e7ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.75,
        "x": 0.02,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Trial process flow from screening to randomization and 30-week treatment period.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdefb179-b518-4f2b-be19-c60c65224e43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "CR=complete clinical remission; CRmin=complete remission on minimal therapy; EoC=end of consolidation; SC=subcutaneous.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c496122-8a35-4778-bd32-d54d4c36c0ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Efgartigimod Phase 3 Trial in Pemphigus - Focus on Potential to Drive Fast-Onset and Steroid Sparing",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26ed4ca7-8be0-4c49-9ad4-66fb12800984",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "665ebf93-7b58-4b72-8862-5282e4429185",
      "evidence": "The slide outlines the methodology and structure of a Phase 3 clinical trial.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 4,
      "beatId": "370e7a7b-342c-4314-a537-20aca17005f0",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Rising Success",
      "beatSlug": "rags-to-riches-rising-success",
      "evidence": "The presentation highlights the company's promising pipeline and clinical trials",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 8,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "9f6093ef-7c49-4bf6-8291-96e05249086f",
      "evidence": "The presentation presents several clinical trials and pipeline opportunities",
      "position": 1,
      "objective": "Highlight the potential of efgartigimod in various indications",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}